NO20002001L - Peptides capable of inhibiting the interaction between presenilines and the <beta> -amyloid peptide or its precursor - Google Patents
Peptides capable of inhibiting the interaction between presenilines and the <beta> -amyloid peptide or its precursorInfo
- Publication number
- NO20002001L NO20002001L NO20002001A NO20002001A NO20002001L NO 20002001 L NO20002001 L NO 20002001L NO 20002001 A NO20002001 A NO 20002001A NO 20002001 A NO20002001 A NO 20002001A NO 20002001 L NO20002001 L NO 20002001L
- Authority
- NO
- Norway
- Prior art keywords
- interaction
- inhibiting
- amyloid peptide
- precursor
- presenilines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
Abstract
Nye polypeptider i stand til i det minste delvis å inhibere interaksjonen mellom presenilin 1 eller presenilin 2 på den ene side og forløperen av P-amyloidpeptid og/eller P-amyloidpeptid på den annen side.Videre beskrives in vitro-tester for påvisning av molekyler og særlig små molekyler i stand til å inhibere interaksjonen.Oppfinnelsens anvendelse på det farmasøytiske området beskrives.Novel polypeptides capable of at least partially inhibiting the interaction between presenilin 1 or presenilin 2 on the one hand and the precursor of β-amyloid peptide and / or β-amyloid peptide on the other hand. particularly small molecules capable of inhibiting the interaction. The application of the invention in the pharmaceutical field is described.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9713384A FR2770217B1 (en) | 1997-10-24 | 1997-10-24 | PEPTIDES CAPABLE OF INHIBITING THE INTERACTION BETWEEN PRESENILINS AND THE PRECURSOR OF B-AMYLOID PEPTIDE AND / OR B-AMYLOID PEPTIDE |
US9567198P | 1998-08-07 | 1998-08-07 | |
PCT/FR1998/002278 WO1999021886A1 (en) | 1997-10-24 | 1998-10-23 | PEPTIDES CAPABLE OF INHIBITING THE INTERACTION BETWEEN PRESENILINS AND THE β-AMYLOID PEPTIDE OR ITS PRECURSOR |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20002001L true NO20002001L (en) | 2000-04-17 |
NO20002001D0 NO20002001D0 (en) | 2000-04-17 |
NO328908B1 NO328908B1 (en) | 2010-06-14 |
Family
ID=26233891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20002001A NO328908B1 (en) | 1997-10-24 | 2000-04-17 | In vitro use of a polypeptide capable of inhibiting the interaction between presenilines and APP. |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1025121B1 (en) |
JP (1) | JP2001521043A (en) |
KR (1) | KR100626475B1 (en) |
CN (1) | CN100429230C (en) |
AU (1) | AU766522B2 (en) |
BR (1) | BR9813105A (en) |
CA (1) | CA2305816C (en) |
CY (1) | CY1112236T1 (en) |
CZ (1) | CZ303226B6 (en) |
HU (1) | HU227660B1 (en) |
IL (2) | IL135751A0 (en) |
NO (1) | NO328908B1 (en) |
WO (1) | WO1999021886A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ303226B6 (en) * | 1997-10-24 | 2012-06-06 | Aventis Pharma S. A. | Process for detecting or isolating compounds intended for treatment of Alzheimer's disease |
DE19909357A1 (en) * | 1999-03-03 | 2000-09-07 | Gerd Multhaup | Copper agonist that binds to the APP copper binding site and / or has an inhibitory effect on the release of the amyloid-Aß peptide |
WO2001062787A1 (en) * | 2000-02-24 | 2001-08-30 | Oxford Glycosciences (Uk) Limited | Diagnosis and treatment of bipolar affective disorder |
WO2002074804A2 (en) * | 2001-03-16 | 2002-09-26 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of binding domains of presenilins and transmembrane proteins for drug screening |
US20080045499A1 (en) * | 2006-02-06 | 2008-02-21 | Elan Pharmaceuticals, Inc. | Preferential Inhibition of Presenilin-1 |
US8129334B2 (en) * | 2006-03-31 | 2012-03-06 | The Regents Of The University Of California | Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory |
JP2009532674A (en) * | 2006-03-31 | 2009-09-10 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | Methods and compositions for treating neurodegenerative disorders and Alzheimer's disease and for improving normal memory |
ES2530141B1 (en) * | 2013-08-26 | 2016-01-15 | Juan Carlos GALLAR RUIZ | Peptide useful as a pharmacological target for the screening of molecules for the treatment and / or prevention of Alzheimer's disease, antibody against it and use of the antibody for the treatment and / or prevention of said disease. |
CN108860921B (en) | 2018-08-08 | 2020-11-20 | 上海鸿研物流技术有限公司 | Collapsible container |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992013069A1 (en) * | 1991-01-21 | 1992-08-06 | Imperial College Of Science, Technology & Medicine | Test and model for alzheimer's disease |
US5986054A (en) * | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
EP0876483A1 (en) * | 1996-01-26 | 1998-11-11 | HSC Research and Development Limited Partnership | Nucleic acids and proteins related to alzheimer's disease, and uses therefor |
CZ303226B6 (en) * | 1997-10-24 | 2012-06-06 | Aventis Pharma S. A. | Process for detecting or isolating compounds intended for treatment of Alzheimer's disease |
-
1998
- 1998-10-23 CZ CZ20001462A patent/CZ303226B6/en not_active IP Right Cessation
- 1998-10-23 KR KR1020007004298A patent/KR100626475B1/en not_active IP Right Cessation
- 1998-10-23 EP EP98951547A patent/EP1025121B1/en not_active Expired - Lifetime
- 1998-10-23 CA CA2305816A patent/CA2305816C/en not_active Expired - Fee Related
- 1998-10-23 IL IL13575198A patent/IL135751A0/en unknown
- 1998-10-23 HU HU0004605A patent/HU227660B1/en not_active IP Right Cessation
- 1998-10-23 CN CNB98810508XA patent/CN100429230C/en not_active Expired - Fee Related
- 1998-10-23 BR BR9813105-2A patent/BR9813105A/en not_active IP Right Cessation
- 1998-10-23 WO PCT/FR1998/002278 patent/WO1999021886A1/en active IP Right Grant
- 1998-10-23 JP JP2000517994A patent/JP2001521043A/en active Pending
-
2000
- 2000-04-17 NO NO20002001A patent/NO328908B1/en not_active IP Right Cessation
- 2000-04-19 IL IL135751A patent/IL135751A/en not_active IP Right Cessation
- 2000-05-03 AU AU31295/00A patent/AU766522B2/en not_active Ceased
-
2011
- 2011-11-24 CY CY20111101152T patent/CY1112236T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CY1112236T1 (en) | 2015-12-09 |
EP1025121A1 (en) | 2000-08-09 |
CZ20001462A3 (en) | 2000-10-11 |
CN100429230C (en) | 2008-10-29 |
WO1999021886A1 (en) | 1999-05-06 |
AU766522B2 (en) | 2003-10-16 |
BR9813105A (en) | 2000-08-15 |
CN1277616A (en) | 2000-12-20 |
IL135751A (en) | 2010-12-30 |
HU227660B1 (en) | 2011-10-28 |
IL135751A0 (en) | 2001-05-20 |
NO328908B1 (en) | 2010-06-14 |
KR100626475B1 (en) | 2006-09-20 |
JP2001521043A (en) | 2001-11-06 |
CA2305816C (en) | 2012-07-10 |
CA2305816A1 (en) | 1999-05-06 |
NO20002001D0 (en) | 2000-04-17 |
EP1025121B1 (en) | 2011-08-24 |
HUP0004605A3 (en) | 2002-09-30 |
HUP0004605A1 (en) | 2001-04-28 |
KR20010024541A (en) | 2001-03-26 |
AU3129500A (en) | 2000-12-14 |
CZ303226B6 (en) | 2012-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69006306D1 (en) | SYNTHETIC PEPTIDES OF THE CONJUGATE OF UBIQUITIN AND HISTONE H2A. | |
AU2672900A (en) | Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides | |
AU4162400A (en) | Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii | |
CA2120358A1 (en) | Hormone analogs with multiple ctp extensions | |
CA2270289A1 (en) | Proteins with enhanced levels of essential amino acids | |
EP2295453A3 (en) | An appetite-suppressing peptide, its compositions and use | |
DE69427370D1 (en) | NEW INTEGRIN-BINDING PEPTIDES | |
RS50101B (en) | Pharmaceutical compositions for immunomodulation | |
ATE280826T1 (en) | CC CHEMOKINCEPTOR C-C CKR-5, DERIVATIVES THEREOF AND USES | |
BR9504791B1 (en) | polypeptide compound and pharmaceutical composition. | |
ES2176284T3 (en) | AMIDAS OF INHIBITING PEPTIDES OF THE CANCER OF HUMAN BEINGS. | |
CA2158058A1 (en) | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof | |
DE69417252D1 (en) | IMPROVED IMMUNOGENIC COMPOSITION AGAINST HUMAN GASTRIN 17 | |
DE69938782D1 (en) | PEPTIDES AS ANTIANGIOGENIC MEDICINAL PRODUCTS | |
NO972620D0 (en) | RANTES peptide and fragments and mixtures comprising it for the treatment of inflammation | |
NO20002001L (en) | Peptides capable of inhibiting the interaction between presenilines and the <beta> -amyloid peptide or its precursor | |
DE69533704D1 (en) | BRADYKININ ANTAGONIST PEPTIDE WITH N-SUBSTITUTED GLYCINES | |
ATE397062T1 (en) | CHIMERIC POLYPEPTIDES CONTAINING SHIGATOXIN FRAGMENT B AND PEPTIDES OF THERAPEUTIC INTEREST | |
NO972849D0 (en) | Peptide p277 analogs and pharmaceutical compositions comprising these for the treatment or diagnosis of diabetes | |
BR9306272A (en) | Peptide and pharmaceutical composition | |
CA2247328A1 (en) | Neuropeptides originating in scorpion | |
EP1251176A3 (en) | Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide | |
DE69427363D1 (en) | Platelet-inhibiting peptides | |
DK0833919T3 (en) | Type F botulinum toxin and its use | |
NZ335136A (en) | Isolated peptides which complex with hla-cw*16 molecules, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |